Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
|Videos|April 17, 2018
Findings With the Antibody Drug Conjugate D3-GPC2-PBD
Author(s)Kristopher Bosse, MD
Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.
Advertisement
Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.
The novel ADC D3-GPC2-PBD was developed for neuroblastoma linking to a specific glypican 2 targeting antibody to the DNA damaging pyrrolobenzodiazepine dimers. This ADC was used in panel of neuroblastoma patient-derived xenografts.
Advertisement
Related to this article
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
3
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5